This OCGN stock forecast article was written by Maria Grishaev, Analyst at I Know First.
Executive Summary
Ocugen had a good year in 2020. The stock price went up by 239.52% despite the COVID-19 pandemic.
A deal to commercialize Covaxin in the U.S. was signed with Bharat Biotech can have an impact on revenue if the FDA will give the vaccine an Emergency Use Authorization.
Quantitative analysis results indicate bullish signals after stock price topped out the moving average line.
OCGN deserves a one-year target price of $13, representing potential revenue growth.
Over the period of June 16th to June 30th, Repligen Corporation (RGEN) stocks prices jumped by 15.8% in 14 days in agreement with the bullish I Know First forecast. Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is the leading manufacturer of Protein A affinity ligands, a critical component of Protein A resins that are used to separate and purify monoclonal antibody therapeutics
Celldex Therapeutics, Inc., incorporated on December 9, 1983, is a bio-pharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. The Company is using the technologies to develop targeted immunotherapeutics consisting of protein-based molecules, such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. The Company’s lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII). Its Glembatumumab vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient’s immune response against their cancer. The Company’s earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. The Company’s pipeline also includes CDX-0158 and CDX-3379.
Source: flickr
Celldex’s pipeline is comprised of immunotherapies and other targeted biologics. Their drug candidates are derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. They are aimed at addressing market opportunities for which they believe current therapies are inadequate or non-existent.
Over the period from 3rd January to 3rd February CLDX saw a stock rise of 130.93% this was the highest performing stock over that period from the BioTech stocks I Know First package.
Over the course of the 2018, the stock reached a high of $2.86 and a low of $0.18, which as a result has the increased attention of keen investors who are following the progress of the asset as it gets closer to a significant historic high price or low value. The stock currently stands at $0.59.
Current I Know First subscribers received a bullish CLDX forecast on 3rd January. With a signal of 1.82 for the month-long time frame.
The graph below shows this remarkable return for CLDX stock over this time period in-line with the I Know First forecast:
Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.
The article was written by Amber Zhou, a Financial Analyst at I Know First.
DVAX Stock Forecast
“We believe there’s a great opportunity for Dynavax to contribute to the overall health of the adult population with diabetes”—said Dr. Rob Janssen, chief medical officer of Dynavax.
(Source: mmm-online.com)
Highlights:
Competitive Edge and Huge Market Potential from Heplisav-B®
Market Doubts about Trial Data of Immuno-Oncology Platform
“We believe that we now have clear paths to accelerated approval for OMS721 in both stem-cell TMA and IgA nephropathy. With breakthrough therapy designations in both of these indications, we look forward to continuing to work closely with FDA and, for stem-cell TMA, we have initiated preparations for a BLA submission”
– Gregory A. Demopulos, M.D., Chairman and CEO of Omeros
Over the 14 days period from May 1st to May 15th, 2018 OMER stock price experienced steep price rise of more than 70%. Taking into account the overall OMER stock performance indicators for the last quarter, it is reasonable to suggest that this is the consequence of the company’s results achieved in 1Q 2018. Based on the press release on May 10, 2018 the following highlights are important to analyse:
1Q 2018 total and OMIDRIA® revenues were $1.6 million, compared to $12.3 million in 1Q 2017; the decrease is the result of the scheduled expiration of OMIDRIA pass-through reimbursement status on January 1, 2018 Net loss in 1Q 2018 was $30.1 million, or $0.62 per
I Know First-Daily Market Forecast, does not provide personal investment or financial advice to individuals, or act as personal financial, legal, or institutional investment advisors, or individually advocate the purchase or sale of any security or investment or the use of any particular financial strategy. All investing, stock forecasts and investment strategies include the risk of loss for some or even all of your capital. Before pursuing any financial strategies discussed on this website, you should always consult with a licensed financial advisor.
